I can only imagine that with the trial protocols, patents and learnings from the ongoing PSI-GAD trial, it should not be too difficult to show the TGA the benefits of psilocybin to be extended to our target condition of Generalised Anxiety Disorder in the near future, as this current rescheduling is just for Treatment Resistant Depression.
Huge regulatory news and great for those suffering from these conditions.
Looking forward to the full details, and wondering if Dr Paul or others from our trial were part of the consultancy committee.
IHL Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
